A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Vaccine

• Publication date

  2001-07-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0264-410X(01)00168-2PMID 11457539
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Respiratory syncytial virus

  2001cited by this paper
• Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.

  2000cited by this paper
• Synthesis and characterization of Respiratory Syncytial Virus protein G related peptides containing two disulfide bridges.

  2000cited by this paper
• Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.

  2000cited by this paper
• Development of combination vaccines.

  1999cited by this paper
• Identification of Multiple Protective Epitopes (Protectopes) in the Central Conserved Domain of a Prototype Human Respiratory Syncytial Virus G Protein

  1999cited by this paper
• The in vitro displacement of adsorbed model antigens from aluminium-containing adjuvants by interstitial proteins.

  1999cited by this paper
• Combination vaccines: issues in evaluation of effectiveness and safety.

  1999cited by this paper
• The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein.

  1999cited by this paper
• Aluminum compounds as vaccine adjuvants.

  1998cited by this paper
• Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na.

  1997cited by this paper
• Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide.

  1997cited by this paper
• Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.

  1997cited by this paper
• Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine.

  1997cited by this paper
• In vivo absorption of aluminium-containing vaccine adjuvants using 26Al.

  1997cited by this paper
• Solution structure of the immunodominant region of protein G of bovine respiratory syncytial virus.

  1996cited by this paper
• Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins.

  1996cited by this paper
• The serum albumin‐binding domain of streptococcal protein G is a three‐helical bundle: a heteronuclear NMR study

  1996cited by this paper
• Interactions in Model Vaccines Composed of Mixtures of Aluminum-Containing Adjuvants

  1995cited by this paper
• Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants.

  1995cited by this paper
• Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants.

  1994cited by this paper
• The Importance of Surface Charge in the Optimization of Antigen–Adjuvant Interactions

  1991cited by this paper
• Predicting the adsorption of proteins by aluminium-containing adjuvants.

  1991cited by this paper
• Point of zero charge of amorphous aluminum hydroxide as a function of adsorbed carbonate.

  1985cited by this paper
• Adsorption of phosphate by aluminum hydroxycarbonate.

  1984cited by this paper
• Vaccine adjuvants.

  1980cited by this paper

• Re-inventing traditional aluminum-based adjuvants: Insight into a century of advancements

  2024influential citation
• Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD)

  2023influential citation
• Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want

  2018cites this paper
• Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action

  2018cites this paper
• Mineral Adjuvants

  2017cites this paper
• Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses

  2016cites this paper
• Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?

  2015cites this paper
• Aluminum Adjuvants: Basic Concepts and Progress in Understanding

  2015cites this paper
• Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants

  2013cites this paper
• Avaliação da resposta imune contra as proteínas L e G do vírus respiratório sincicial humano.

  2012cites this paper
• Respiratory syncytial virus vaccine development

  2011cites this paper
• Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.

  2011cites this paper
• New insights for development of a safe and protective RSV vaccine

  2010cites this paper
• Aluminum adjuvants: preparation, application, dosage, and formulation with antigen.

  2010cites this paper
• Peptides as tools and drugs for immunotherapies

  2007cites this paper
• 13 – Mineral adjuvants

  2006cites this paper
• Formulation of botulinum neurotoxin heavy chain fragments for vaccine development: mechanisms of adsorption to an aluminum-containing adjuvant.

  2005cites this paper
• Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge.

  2004cites this paper
• Proteomics: Biomedical and Pharmaceutical Applications

  2004cites this paper
• Proteomics for Development of Immunotherapies

  2004cites this paper
• Respiratory Syncytial Virus

  2003cites this paper
• DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine.

  2002cites this paper
• Structure-antigenicity relationship studies of the central conserved region of human respiratory syncytial virus protein G.

  2002cites this paper
• Gamma Interferon-Dependent Protection of the Mouse Upper Respiratory Tract following Parenteral Immunization with a Respiratory Syncytial Virus G Protein Fragment

  2002cites this paper
• Synthesis and Solution Three-Dimensional Structure of the Immunodominant Region of Protein G of Human RSV

  2001cites this paper